Cardiol gains U.S. patent for heart drugs to 2040

Executive Summary

• Cardiol Therapeutics received a Notice of Allowance from the USPTO for a patent application covering Cannabidiol Compositions for treating heart conditions, providing broad IP protection for CardiolRx and CRD-38.
• The patent protection extends through October 2040, covering an extensive range of cardiac conditions including heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from anti-cancer therapies, and atherosclerosis.
• The company highlighted that this milestone, combined with its U.S. orphan drug designation for pericarditis, strengthens its market position and supports its global clinical and commercial strategy for late-stage programs.

Key Details

• Patent Scope: The allowance covers "Cannabidiol Compositions for Use in Treating Heart Conditions."
• Protection Duration: The patent protection is valid until October 2040.
• Protected Indications: The IP covers the use of CardiolRx and CRD-38 for:
  • Heart failure
  • Myocarditis
  • Acute pericarditis
  • Inflammatory cardiomyopathy
  • Cardiac toxicity from anti-cancer therapies
  • Atherosclerosis
• Strategic Context: The CEO noted this fortifies the IP portfolio alongside the U.S. orphan drug designation for pericarditis.
• Pipeline Updates Mentioned:
  • Archer Program: Top-line findings from the randomized, double-blind, placebo-controlled Phase II trial of CardiolRx in acute myocarditis will be presented at the European Society of Cardiology Annual Meeting in Trieste, Italy, on Nov. 29.
  • Maveric Program: Pivotal Phase III trial in recurrent pericarditis is continuing with accelerating patient enrollment across leading U.S. cardiovascular research centers.
  • CRD-38: Preparation is underway for the first-in-human clinical evaluation of this novel subcutaneously administered therapy for inflammatory heart disease, including heart failure.

Notable Quotes

• "This important milestone extends our I.P. protection to the world's largest pharmaceutical market... This expanded exclusivity coverage also reinforces the long-term value of our pipeline as we advance late-stage clinical programs... and as we prepare to initiate first-in-human clinical evaluation of CRD-38." — David Elsley, President and CEO
• "This patent allowance comes at an opportune time, adding extensive intellectual property protection in new areas of heart disease that have been identified for potential research expansion based on the recently reported top-line Archer findings." — Dr. Andrew Hamer, Chief Medical Officer and Head of R&D